Last Updated on September 30, 2024 by The Health Master
MPOX vaccine
China has taken a significant step towards combating the global MPOX outbreak with the approval of a domestic vaccine candidate for clinical trials. Developed by Sinopharm, the MPOX vaccine holds the promise of becoming the country’s first experimental dose to battle this deadly disease.
A Domestic Solution to a Global Problem
The vaccine, created by the Shanghai Institute of Biological Products and administered by Sinopharm, is designed to play a crucial role in preventing and controlling MPOX infections.
This marks a significant development for China, which currently lacks an approved MPOX vaccine.
While a few vaccines have been approved in other countries like the United States, Canada, the European Union, Japan, and Russia, China’s domestic vaccine candidate offers hope for a more accessible and tailored solution.
Accelerating Vaccine Development
The National Medical Products Administration, China’s top drug regulator, has implemented streamlined channels to expedite the approval process for novel drugs and vaccines.
This initiative aims to address urgent health needs, such as the MPOX outbreak, and ensure timely access to life-saving treatments.
A Promising Vaccine Candidate
The newly developed vaccine is a replication-deficient vaccine based on the MVA strain.
This description aligns with Jynneos, the world’s first MPOX vaccine approved by the Food and Drug Administration in the United States.
The similarity in vaccine technology suggests that the Chinese vaccine could potentially offer comparable efficacy and safety.
Addressing a Global Health Emergency
The World Health Organization (WHO) declared the MPOX outbreak in Africa a public health emergency of international concern in August 2024.
This designation highlights the severity of the outbreak and the urgent need for effective prevention and control measures.
While the WHO previously declared a global emergency in July 2022, it was lifted in May 2023 due to a decline in international cases.
However, the recent resurgence of cases has prompted renewed concerns.
China’s Response to the MPOX Outbreak
China has reported a significant number of MPOX cases, with over 2,567 confirmed infections by the end of July.
The development of a domestic vaccine is a crucial step in China’s efforts to combat the outbreak and protect its population from the disease.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Disclaimer: This content, provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. The Health Master does not claim responsibility for this information.
Over 340 Pharma Companies overdue for USFDA inspection in India and China
USFDA approval granted for Albendazole Tablets USP, 200 mg: Alembic
Pharma Industry seeks relief: Decriminalization of DPCO provisions
QR Code Mandate: Pharma Industry calls for Financial Support
Drug recall: Baxter recalls various batches of Tisseel due to dissolution time
USFDA approval granted for Theophylline Extended-Release Tablets
Pharma Retailers demand redesign of medicine packs: Strip Cutting
USFDA inspection with positive VAI to Dr. Reddy’s Lab for its API facility
Govt issues new uniform code for marketing of Medical Devices
Over 340 Pharma Companies overdue for USFDA inspection in India and China
APTI demands reservation of all Pharma Jobs for Pharmacy Graduates
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
